Early rhythm control significantly reduced the risk of major cardiovascular events (HR 0.73) compared to usual care in patients with early-stage atrial fibrillation.
Cohort (n=7,161)
Yes
Does an early rhythm control strategy reduce major cardiovascular events in patients with early-stage atrial fibrillation?
In a retrospective cohort of early-stage AF patients, early rhythm control was associated with a reduced risk of MACE and heart failure compared to usual care.
Effect estimate: HR 0.73 (95% CI 0.57-0.93)
Absolute Event Rate: 14% vs 22%
p-value: p=0.02
-VASc score. To elucidate this, we conducted the present study.A retrospective cohort study was conducted using the Yinzhou Regional Health Care Database. We included all patients diagnosed with AF within 1 year and excluded those without age/sex information, without ERC/UC treatment prescription, or with ongoing cancer. The primary outcome was major cardiovascular events (MACE). We used inverse probability of treatment weighting (IPTW) for covariate weighting.A total of 7,161 patients diagnosed with early-stage AF were included in this study. Of them, 2,248 and 4,913 were included in the ERC and UC groups, respectively. During the mean follow-up period of 3.2 years (27,945 person-year), and after IPTW, ERC showed significantly lower risk for MACE (HR: 0.75 0.61, 0.96, P = 0.02) and heart failure (HF; HR: 0.71 0.54, 0.95, P = 0.01). No significant results were obtained for stroke, cardiovascular death, or all-cause mortality.ERC is more beneficial to early-stage Persons with AF than UC for MACEs, particularly HF.
Liu et al. (Wed,) conducted a cohort in Early-stage Atrial Fibrillation (n=7,161). Early rhythm control vs. Usual care (rate control) was evaluated on Major cardiovascular events (MACE) (HR 0.73, 95% CI 0.57-0.93, p=0.02). Early rhythm control significantly reduced the risk of major cardiovascular events (HR 0.73) compared to usual care in patients with early-stage atrial fibrillation.